Revised EudraVigilance access policy is adopted by EMA Management Board
The European Medicines Agency (EMA) will give increased access to reports on suspected adverse reactions to medicines authorised in the European Union (EU), while guaranteeing that personal data will be fully protected.
This follows a revision of EudraVigilance Access policy, which was adopted by EMA’s Management Board at its December 2015 meeting. The adoption followed a public consultation that generated nearly 400 comments which have been taken into account in the final policy.
EudraVigilance is the European database of all suspected adverse reactions reported with medicines authorised in the European Economic Area (EEA). Managed by EMA on behalf of the EU medicines regulatory network, EudraVigilance receives more than one million adverse drug reaction (ADR) reports every year. The large datasets included in the database provide the backbone for the continuous safety monitoring of medicines in the EU.
The Agency has made data from EudraVigilance publicly available since 2011. At the time, EMA defined levels of access to information on ADR reports for medicines in EudraVigilance for each stakeholder group: European regulators; healthcare professionals, consumers and patients; marketing-authorisation holders and academia. Information from EudraVigilance on centrally authorised products and substances commonly used in medicines is available through a dedicated public website.
The revised policy takes into account the changes to the system of safety monitoring of medicines introduced by pharmacovigilance legislation, such as new transparency provisions, the introduction of direct patient reporting across all EU Member States and a simplification of the reporting of adverse reaction reports for pharmaceutical companies.
Key changes include:
These changes will come into effect in the third quarter of 2017 in parallel with EMA implementing a series of technical improvements to the EudraVigilance system.